摘要： Significant improvements in disease management have been achieved in the past few decades. Using cancer as an example, survival rates have increased dramatically in economically developed countries, according to the World Cancer Report published by WHO in 2014.1 One of the highlights is the average 5-year survival rate of children diagnosed before the age of 15 years in Britain increased from less than 30% in 1966-70 to almost 80% in 1996-2000. The improvement can be attributed to the establishment of early screening and awareness programs, identification of a large number of genetic or non-genetic risk factors or markers, and availability of diverse therapeutic strategies including surgery and treatments using radioactive reagents, small molecules, or biological drugs. Still, cancer remains one of the major causes of deaths worldwide, affecting millions of people. Survival rates in developing countries are poor, and the global and regional burden of cancer in terms of both incidence and mortality keep increasing along with the growing population and aging society. Further improvement heavily relies on early diagnosis, wide access to treatment options, and discovery of more effective biomarkers as well as anticancer drugs with high efficacy. Such demands are also applied to diagnosis and cure for all other diseases, calling for rapid advancements in high-throughput screening (HTS) technologies that can efficiently test a large number of targets and samples, monitor diverse enzymatic processes in situ, and effectively identify biologically active substances.2